Clinical Scorecard: Assessment of HBV and HCV Seroprevalence through Rapid Point-of-Care Testing in Earthquake Survivors in Southeastern Türkiye

At a Glance

Key Highlights

• HBV seroprevalence in Türkiye is 4%, with Southeastern Anatolia at 7.3%
• HCV seroprevalence in Türkiye ranges from 0.5% to 1%
• Rapid point-of-care tests provide quick and reliable screening for HBV and HCV
• High-risk groups for HCV include individuals who received blood products before 1996 and people who inject drugs
• The study aimed to evaluate HBV and HCV prevalence among earthquake survivors using rapid testing

Guideline-Based Recommendations

Diagnosis

• Use rapid point-of-care tests for screening HBV and HCV in high-risk populations

Management

• Implement vaccination programs for HBV and provide education on HCV transmission risks

Monitoring & Follow-up

• Regular screening in temporary shelters and communal living areas for at-risk populations

Risks

• Increased transmission risk due to unscreened blood transfusions and poor hygiene conditions post-earthquake

Patient & Prescribing Data

Earthquake survivors aged 18 and older residing in container cities

Vaccination programs have reduced acute HBV cases; ongoing education needed for HCV prevention

Clinical Best Practices

• Conduct rapid testing in emergency settings to identify and manage HBV and HCV infections
• Ensure access to vaccination for high-risk groups
• Educate communities on safe practices to prevent viral transmission

References

• Study on HBV and HCV prevalence